Structure-Activity Relationship
"Structure-Activity Relationship" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
| Descriptor ID |
D013329
|
| MeSH Number(s) |
G02.111.830 G07.690.773.997
|
| Concept/Terms |
Structure-Activity Relationship- Structure-Activity Relationship
- Relationship, Structure-Activity
- Relationships, Structure-Activity
- Structure Activity Relationship
- Structure-Activity Relationships
|
Below are MeSH descriptors whose meaning is more general than "Structure-Activity Relationship".
Below are MeSH descriptors whose meaning is more specific than "Structure-Activity Relationship".
This graph shows the total number of publications written about "Structure-Activity Relationship" by people in this website by year, and whether "Structure-Activity Relationship" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 5 | 6 |
| 2018 | 0 | 4 | 4 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Structure-Activity Relationship" by people in Profiles.
-
Deconstructing fibrin(ogen) structure. J Thromb Haemost. 2025 Feb; 23(2):368-380.
-
Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy. J Med Chem. 2024 Apr 11; 67(7):5333-5350.
-
Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition. Bioorg Med Chem Lett. 2023 06 15; 90:129328.
-
Nonhydrolyzable d-phenylalanine-benzoxazole derivatives retain antitubercular activity. Bioorg Med Chem Lett. 2023 01 15; 80:129116.
-
Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorg Med Chem. 2022 03 15; 58:116645.
-
1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded a-Synuclein Aggregates. ChemMedChem. 2022 01 19; 17(2):e202100611.
-
A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells. Bioorg Chem. 2021 11; 116:105340.
-
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021 Jan 01; 209:112866.
-
Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. Eur J Med Chem. 2020 Aug 15; 200:112417.
-
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021 01; 35(1):75-89.